Skip to content

Food is medicine: Testing 'medically tailored groceries' for pregnant women with food insecurity and high risk pregnancies in Australia

‘Medically Tailored Groceries’ to reduce the incidence of adverse perinatal outcomes: protocol for a randomised controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12624001407583
Acronym
Preg-MTG
Enrollment
232
Registered
2024-11-28
Start date
2025-05-06
Completion date
2027-06-30
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Healthy eating advice is recommended by guidelines as a mainstay therapy for women at high risk or those who have developed gestational diabetes mellitus (GDM), prior to pharmacotherapy. GDM is a condition characterised by higher-than-normal blood sugar levels during pregnancy with immediate and long-term health consequences. 'Food is Medicine' programs aim to integrate nutrition interventions into the health care system to help improve the clinical population's diets and complement pharmacologic treatment of diseases. 'Medically Tailored Groceries' is one such approach whereby clinicians and other health professionals prescribe free or subsidised healthy foods to people who experience food insecurity as part of their treatment. We will assess the effect of medically tailored grocery program on the incidence of adverse perinatal outcomes for women with food insecurity and at high risk of GDM compared to usual care. We will conduct a randomised control trial of a medically tailored grocery intervention in pregnancy women at high risk of GDM, who have difficulty buying or eating nutritious food. Intervention participants will be prescribed healthy food boxes from < 20 weeks gestation to child birth. In addition, intervention participants will also receive three consultations with a dietitian. The primary outcome is the incidence (yes/no) of any one of the following: overt diabetes in pregnancy, GDM, pregnancy related hypertension, gestational weight gain above recommendations, unplanned caesarean section, large/small for gestational age, preterm birth, stillbirth/neonatal death. Gestational weight gain, diet quality, and food and nutrition insecurity are pre-specified secondary outcomes. Cardiometabolic outcomes, patient-reported outcome measures, and the feasibility and acceptability of the produce prescription program will also be assessed. Finally, a sub-sample of participants will be interviewed to explore how the program worked (or did not work) for them, and ways the program can be improved and scaled up. And there will be opportunities for participants to opt-in to a microbiome sub-study, and for the partners to participate in the Partner sub-study (assessing the co-benefits of a produce prescription intervention). We hypothesise that the intervention group will have a reduced incidence of adverse perinatal complications, improved diet quality, food/nutrition insecurity and reduced gestational weight gain during pregnancy compared to the control group. We anticipate that the program will be highly acceptable to pregnant women and suitable for scale up as part of healthcare.

Interventions

Each intervention participant will receive a 'prescription' for healthy food boxes delivered to their homes weekly by the study food supplier until they have given birth. The prescription will also contain simple recipes using foods availability in the health food boxes. Content of the healthy food boxes will be pre-determined by the study team and the food supplier, and will include fruit, vegetables, nuts and seeds, and low glycaemic index whole grain products that are appropriate for pregna

Each intervention participant will receive a 'prescription' for healthy food boxes delivered to their homes weekly by the study food supplier until they have given birth. The prescription will also contain simple recipes using foods availability in the health food boxes. Content of the healthy food boxes will be pre-determined by the study team and the food supplier, and will include fruit, vegetables, nuts and seeds, and low glycaemic index whole grain products that are appropriate for pregnant women and recommended by the Australian Dietary Guidelines. The amount provided will be tailored to household size, with the aim of supporting healthier food intake and it is not designed to replace all food intake. The prescription will allow the participants to take part in telephone appointments (up to 30 minutes) up to three times between randomisation and 28 weeks of gestation at approximately 2, 4 and 8 weeks post-randomisation with a trained accredited dietitian to support improvement in diet quality. The decision to take part in these dietitian consults will be at the participant's discretion. The dietitian will provide dietary advice, including a specific focus on how to cook the healthy foods provided to the participants. Participants will be advised to avoid foods that they are allergic or intolerant to and continue their usual medications, and any changes to medication requirements will be at the discretion of their treating clinician. To monitor adherence to the intervention, study staff who conduct the diet consultations will log the number of dietary counselling sessions with each participant. Participants will also be asked to complete a self-administered Process Evaluation questionnaire related to produce acceptability and uptake at gestation weeks 24-28 and 35-38. Each participant will receive a $100 voucher after the completion of data collection at baseline and mid-point, and $150 after data collection at the end-point (total $350). The vouchers can be used to purchase groceries at a local food retailer of their choice. There will be no specific recommendations about how the vouchers are to be spent. At the end of the study, informant interviews (up to 40 minutes in duration) will be conducted by phone (i.e., Microsoft teams or Zoom audio function) with one to two purposely selected representatives each from the food supplier (Managing Directors/Chief Executive Officers and other staff engaged in the intervention), clinical staff, and study staff as well as 12 purposely selected intervention participants (with a range of characteristics). A subset of 12 intervention participants will be invited to take part in a semi-structured interview (up to 30 minutes) to obtain an in-depth understanding of what worked or not, what and how the intervention could be improved, and what were the challenges and enablers of intervention uptake. For the food supplier interviews, study staff are in contact with them as part of running the study and will ask who may be willing to be interviewed. For clinicians, relationships exist (some are collaborators on this study) and these contact details will be used to ask who may be willing to be interviewed and provide the Information Statement to them. For study staff, willing interviewees will self-nominate and access the Information Statement and use our usual means of contacting each other. The interviews will seek to obtain an in-depth understanding of what worked (or not), for whom and how, challenges and facilitators, and any adaptations throughout the implementation process. For all key informant interviews (except among trial participants), verbal consent will be obtained at the start of the interviews as per the verbal consent script and consent will be audio-recorded.

Sponsors

The George Institute for Global Health
Lead SponsorOther Collaborative groups

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Blinded (masking used) (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Pregnant women aged 18 years or over. * At high risk of GDM according to ADIPS Guidelines (at least one of the following risk factors of GDM): - previous hyperglycaemia in pregnancy - previously elevated blood glucose level - maternal age 40 years or over - a family history of diabetes mellitus (1st degree relative with diabetes including sister with GDM) - body mass index of >30 kg/m2 - previous macrosomia (baby with birthweight > 4500g or > 90th percentile) - polycystic ovary syndrome - medications (corticosteroids or antipsychotics) - Asian, Indian subcontinent, Aboriginal, Torres Strait Islander, Maori, Pacific Islander, Middle Easter, non-white African ethnicity * Women less than 16 weeks gestation. * Food insecure based on a six-item questionnaire OR facing financial hardship based on a four-item questionnaire (adapted from the Household, Income and Labour Dynamics in Australia (HILDA) and Protocol for Responding to and Assessing Patients’ Assets, Risks, and Experiences (PRAPARE) surveys) OR has a Low-Income Health Care concession Card. * Able to read or speak English OR speak one of the 'Top 2' languages spoken, other than English, by women in the antenatal clinic at each study site (Canterbury: Arabic and Banagali; Campbelltown: Arabic and Vietnamese; St George: Spanish and Mongolian; Nepean: Dari and Hindi). * Singleton pregnancy confirmed by ultrasound. * Planned antenatal care at the same or another participating trial centre (e.g., hospital or GP) throughout pregnancy. * Lives within the distribution zone of the study food supplier.

Exclusion criteria

* Pre-pregnancy BMI <23 kg/m2 for women with an Asian, Middle Eastern, Black African or African-Caribbean family background (as per NICE guidelines) or <25 kg/m2 for all other ethnicities * Unable or unwilling to provide informed consent * Pre-pregnancy type 1 or type 2 diabetes. * Severe congenital abnormality on ultrasound. * Termination planned. * Anyone not planning to stay within their home in Sydney area for the remainder of their pregnancy. * Living in a facility that provides meals. * Does not have refrigerators at home for storing study foods. * Existing medical conditions that severely limits dietary intake, requires individualised diets. * Those with severe food allergies (but those with gluten or dairy intolerances can participate). * Those with active cancer, patients with renal failure (stages 4 or 5), severe liver disease (stage 4), advanced heart failure (stage D) and psychiatric conditions requiring in-patient admission. * People participating in any other lifestyle modification research projects. * Another household member already participating in the study,

Outcome results

None listed

Source: ANZCTR · Data processed: Sep 19, 2026